{"title":"Small fiber neuropathy","authors":"Teresa Sevilla , Lucía Galán Dávila","doi":"10.1016/j.medcle.2025.106950","DOIUrl":null,"url":null,"abstract":"<div><div>Small fiber neuropathy (SFN) are a frequent cause of consultation in neurology. The estimated prevalence is of minimum 53 cases/100.000 inhabitants. The most frequent symptoms are neuropathic pain and dysautonomic disfunction. Symptoms, examination, neurophysologic test and skin biopsy are the pillars in its diagnosis. In the last years new causes of SFN has been described as for example mutations in sodium channel or immune causes as TS-HDS, FGFR-3 y plexina D1. Nowadays the treatment of SFN is mainly symptomatic including antidepressives and antiepileptics in a essay-mistake approach. However this new knowledge in the field may lead to a better definition of phenotype and genotype and a more personalized treatment.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"165 3","pages":"Article 106950"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina clinica (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2387020625003936","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Small fiber neuropathy (SFN) are a frequent cause of consultation in neurology. The estimated prevalence is of minimum 53 cases/100.000 inhabitants. The most frequent symptoms are neuropathic pain and dysautonomic disfunction. Symptoms, examination, neurophysologic test and skin biopsy are the pillars in its diagnosis. In the last years new causes of SFN has been described as for example mutations in sodium channel or immune causes as TS-HDS, FGFR-3 y plexina D1. Nowadays the treatment of SFN is mainly symptomatic including antidepressives and antiepileptics in a essay-mistake approach. However this new knowledge in the field may lead to a better definition of phenotype and genotype and a more personalized treatment.